Axsome Therapeutics stock is up 16% year to date. Why Wall Street thinks it has even more room to run The Motley Fool 11h Wall Street Stock Markets (World) Stock Market (US)
European regulators recall Amgen’s rare disease drug Tavneos BioWorld 3d Rare Diseases Biotech Article paywall
GLP-1 demand is soaring. 2 Stocks that could benefit from this (hint: Not Eli Lilly or Novo Nordisk) The Motley Fool 00:00 Sat, 15 Aug Novo Nordisk Pharma Regeneron
Eli Lilly's GLP-1 pricing problem is actually a growth opportunity The Motley Fool 19:11 Thu, 13 Aug Pharma Mounjaro
Why this growth stock manager likes both the AI trade and Eli Lilly MorningStar.com 11:18 Wed, 12 Aug AI Pharma IT
